SynthesisJournal of medical imaging and radiation oncology2026
Diagnostic and Therapeutic Impact of FDG-PET/CT Following MRI Staging in Anal Cancer: A Systematic Review and Meta-Analysis.
Synthesis in Journal of medical imaging and radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAccurate staging is essential in anal cancer to guide therapy and prognostication. While MRI remains the modality of choice for local staging, its limitations in assessing nodal and distant metastases have prompted evaluation of FDG PET/CT as an adjunct. The American College of Radiology recommends FDG-PET/CT as a complementary modality for initial staging, particularly for nodal assessment.
methodsA systematic search of PubMed, EMBASE, Web of Science and Scopus was conducted up to August 2025 following PRISMA guidelines (PROSPERO ID: CRD1149778). Studies included reported adult patients with biopsy-proven anal squamous cell carcinoma who underwent both MRI and FDG-PET/CT for initial staging. Primary outcomes included per-patient sensitivity/specificity for metastasis, changes in TNM staging and therapeutic outcomes, including management modification.
resultsSix studies (n = 246) met the inclusion criteria. Five studies reported on staging changes, where FDG-PET/CT altered staging in 22.5% (95% CI: 12.3-34.7) of patients, more commonly through upstaging than downstaging (16.2% [95% CI: 10.7-22.5] vs. 6.3% [95% CI: 1.5-14.2]). Upstaged patients were predominantly nodal (74.6% [95% CI: 63.2-83.1]). Previously occult metastases were identified with FDG PET/CT in 3% (95% CI: 1.1-6.9) of patients. Management changes occurred in 20.7% (95% CI: 14.9-27.4), predominantly through radiotherapy field expansion or dose modifications.
conclusionFDG-PET/CT following MRI provides incremental diagnostic and therapeutic value in anal cancer staging, through refining nodal and metastatic staging and influencing radiotherapy planning, supporting its routine integration to optimise staging accuracy and management decisions.
trial registrationPROSPERO: CRD42023446290.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.